FR2742055A1 - Liquid plant extract mixture - Google Patents
Liquid plant extract mixture Download PDFInfo
- Publication number
- FR2742055A1 FR2742055A1 FR9514702A FR9514702A FR2742055A1 FR 2742055 A1 FR2742055 A1 FR 2742055A1 FR 9514702 A FR9514702 A FR 9514702A FR 9514702 A FR9514702 A FR 9514702A FR 2742055 A1 FR2742055 A1 FR 2742055A1
- Authority
- FR
- France
- Prior art keywords
- plant
- extract
- activity
- liquid
- mixture according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9741—Pteridophyta [ferns]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9761—Cupressaceae [Cypress family], e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9755—Gymnosperms [Coniferophyta]
- A61K8/9767—Pinaceae [Pine family], e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
L'invention concerne des mélanges d'extraits de plantes et leurs utilisations, notamment pour le traitement local symptomatique des surcharges adipeuses sous-cutanées localisées. The invention relates to mixtures of plant extracts and their uses, in particular for the local symptomatic treatment of localized subcutaneous adipose overloads.
Les surcharges adipeuses sous cutanées localisées ou lipodystrophies localisées de type gynoide se rencontrent essentiellement dans les régions adipeuses suivantes : rétrodeltoïdienne, mammaire, sous-ombilicale, fessière, rétrosacrée, hanches, cuisses (face antérieure et face interne à la racine du genou). Localized subcutaneous adipose overloads or localized gynoid lipodystrophies are mainly encountered in the following adipose regions: retrodeltoid, mammary, sub-umbilical, gluteal, retrosacral, hips, thighs (anterior face and internal face at the root of the knee).
Le mécanisme normal est un stockage des graisses dans les adipocytes, cellules situées dans l'hypoderme groupées en petits amas limités par des travées de soutien constituant le tissu conjonctif. Dans ce tissu de soutien se trouvent les vaisseaux sanguins qui permettent d'éliminer les métabolites et d'apporter l'oxygène. The normal mechanism is a storage of fat in adipocytes, cells located in the hypodermis grouped in small clusters limited by support spans constituting the connective tissue. In this support tissue are the blood vessels that help eliminate metabolites and provide oxygen.
Ces graisses sont transformées selon le besoin de l'organisme en acides gras libres par un processus appelé lipolyse. These fats are transformed according to the body's need into free fatty acids by a process called lipolysis.
Si le mécanisme s'enraye, il y a accumulation anormale de graisses dans les adipocytes, ce qui constitue le stade congestif, puis compression des vaisseaux, les échanges circulatoires ne peuvent plus se faire, ce qui entraîne rétention d'eau et de toxines : ceci constitue le stade de stase. If the mechanism stops, there is an abnormal accumulation of fat in the adipocytes, which constitutes the congestive stage, then compression of the vessels, the circulatory exchanges can no longer take place, which leads to retention of water and toxins: this constitutes the stage of stasis.
Les fibres de collagène environnantes se densifient, des nodules se forment avec dégénérescence des adipocytes. Le collagène se raréfie, le tissu conjonctif devient mou et flasque, prématurément vieilli. Les faisceaux vasculonerveux comprimés empêchent tout échange et conduisent à une peroxydation des acides gras insaturés. The surrounding collagen fibers densify, nodules are formed with degeneration of the adipocytes. Collagen is becoming scarce, the connective tissue becomes soft and flaccid, prematurely aged. The compressed vascular bundles prevent exchange and lead to peroxidation of unsaturated fatty acids.
Trois phénomènes coexistent dans la lipodystrophie localisée et s'autoentretiennent:
- formation de nodules cellulitiques où l'on observe accumulation de graisses, de toxines par peroxydation et d'eau;
- dégénérescence du tissu conjonctif de soutien environnant due à l'attaque du collagène et de ltélastine;
- insuffisance circulatoire localisée.Three phenomena coexist in localized lipodystrophy and are self-sustaining:
- formation of cellulite nodules where we observe accumulation of fats, toxins by peroxidation and water;
- degeneration of the surrounding connective support tissue due to attack by collagen and telastin;
- localized circulatory failure.
Les extraits végétaux forment la base de nombreux produits amincissants. Plant extracts form the basis of many slimming products.
On connaît des plantes, notamment le kola, le guarana, le caféier, le thé contenant des xanthines dont l'action liporéductrice est connue. En effet, les xanthines agissent en bloquant la phospho-diestérase et en activant l'adénylcyclase, aboutissant à l'élévation du taux d'AMPc dans les adipocytes et, par suite, à la libération d'acides gras libres. Plants are known, in particular cola, guarana, coffee, tea containing xanthines, the liporeductive action of which is known. In fact, xanthines act by blocking phosphodiesterase and activating adenylcyclase, leading to an increase in the level of cAMP in adipocytes and, consequently, to the release of free fatty acids.
On sait que les plantes contenant des analogues de vitamine P ont une action tonicapillaire. Plants containing vitamin P analogs are known to have a tonicapillary action.
A titre d'exemple de telles plantes, on citera l'arnica, le cyprès, le gui,
I'hamamelis, le mélilot, le marronnier, le millefeuille, le petit houx, la verveine, la vigne rouge ainsi que divers citrus.Examples of such plants include arnica, cypress, mistletoe,
I'hamamelis, sweet clover, horse chestnut, yarrow, holly, verbena, red vine and various citrus fruits.
Par ailleurs, les flavonoïdes ont une activité plus ou moins importante sur la résistance capillaire et sur la protection vis-à-vis de l'adrénaline, favorisant ainsi la synthèse d'ATP antilipoperoxydante. In addition, flavonoids have a more or less significant activity on capillary resistance and on protection against adrenaline, thus promoting the synthesis of antilipoperoxidative ATP.
Un certain nombre de plantes telles que l'hydrocotyle, la verveine, la piloselle, I'ulmaire, I'orthosiphon sont connues pour leur action anti-oedémateuse, du fait de leur action désinfiltrante et tonicapillaire. A certain number of plants such as hydrocotyle, verbena, piloselle, ulmaire, orthosiphon are known for their anti-edematous action, because of their disinfiltrating and tonicapillary action.
Les plantes contenant de la silice ou des alginates sont particulièrement recherchées pour leur activité sur la régénération tissulaire. Plants containing silica or alginates are particularly sought after for their activity on tissue regeneration.
Ainsi, la prêle est particulièrement connue pour sa concentration en silice exceptionnelle dans le règne végétal. Horsetail is therefore particularly known for its exceptional silica concentration in the plant kingdom.
Le fucus et les laminaires sont, quant à eux, bien connus pour leur richesse en alginates. Fucus and kelp are well known for their richness in alginates.
Un certain nombre de plantes sont bien connues pour affermir le tissu cutané dès les premières applications, agissant ainsi comme des tenseurs cutanés. A number of plants are well known for firming the skin tissue from the first applications, thus acting as skin tensors.
A titre d'exemple de plantes présentant cette action "tenseur", on citera l'aigremoine, I'angélique, I'églantier, la marjolaine, la pervenche, le plantain, le lierre grimpant, le ratanhia, la sauge, le géranium. By way of example of plants exhibiting this "tightening" action, we may mention Agrimony, Angelica, Rosehip, Marjoram, Periwinkle, Plantain, Creeping Ivy, Ratanhia, Sage, Geranium.
Par ailleurs, il est connu d'ajouter dans les compositions à base de plantes un principe actif permettant de favoriser la pénétration cutanée des principes actifs renfermés dans les plantes lors de leur application sur la peau. Furthermore, it is known to add to the herbal compositions an active principle making it possible to promote the skin penetration of the active principles contained in the plants during their application to the skin.
A cet effet, on choisit généralement un extrait de plante à activité révulsive. To this end, a plant extract with revulsive activity is generally chosen.
A titre d'exemple non limitatif de plantes présentant une telle activité, on citera les plantes de la famille des renonculacées contenant de la protoanémonine qui se transforme en anémonine lors du séchage de la plante. Un exemple bien connu de telles plantes est la clématite. By way of nonlimiting example of plants exhibiting such activity, mention will be made of plants of the renonculaceae family containing protoanemonin which transforms into anemonine during drying of the plant. A well-known example of such plants is clematis.
La demanderesse poursuivant des recherches approfondies en vue de mettre au point des compositions à base de plantes pour le traitement local symptomatique des surcharges adipeuses sous-cutanées localisées a sélectionné des plantes pour leurs principes actifs précisés ci-dessus et réalisé un nombre considérable d'associations. Elle a ainsi pu déterminer des associations et des proportions particulières permettant d'obtenir une activité synergique symptomatique sur les différents facteurs des lipodystrophies localisées. The Applicant, pursuing in-depth research with a view to developing herbal compositions for the local symptomatic treatment of localized subcutaneous adipose overloads, has selected plants for their active principles specified above and has produced a considerable number of associations. . It was thus able to determine specific associations and proportions allowing symptomatic synergistic activity to be obtained on the various factors of localized lipodystrophies.
Ainsi, la demanderesse a plus précisément mis au point de nouveaux mélanges d'extraits liquides de plantes qui trouvent particulièrement leurs applications dans des compositions cosmétiques ou pharmaceutiques, notamment dermatologiques, destinées au traitement local symptomatique des surcharges adipeuses sous cutanées localisées. Thus, the Applicant has more precisely developed new mixtures of liquid plant extracts which find their applications particularly in cosmetic or pharmaceutical compositions, in particular dermatological compositions, intended for the local symptomatic treatment of localized subcutaneous adipose overloads.
Par "extrait liquide", on entendra au sens de l'invention des extraits obtenus par extraction au moyen d'un solvant liquide des plantes ou parties de plantes concernées. By "liquid extract" is meant within the meaning of the invention extracts obtained by extraction with a liquid solvent from the plants or parts of plants concerned.
Au cours de ses recherches, la demanderesse a également découvert que, parmi les extraits liquides entrant les mélanges sélectionnés, certains trouvaient pour la première fois leur application dans le traitement visé. Cest le cas, en particulier, des extraits de pamplemousse. During its research, the applicant also discovered that, among the liquid extracts entering the selected mixtures, some found their application for the first time in the intended treatment. This is the case, in particular, grapefruit extracts.
Ainsi, selon l'une de ses caractéristiques essentielles, l'invention concerne un mélange d'extraits liquides de plantes contenant, exprimées en pourcentages en poids, les proportions suivantes de différents extraits liquides de plantes, chaque quantité d'extraits liquides obtenus correspondant à l'extraction de la même quantité de plantes fraîches:
- 8 à 25 % d'extrait liquide d'au moins une plante contenant des xanthines conférant audit extrait une activité liporéductrice,
- 8 à 25 % d'extrait liquide d'au moins une plante contenant un analogue de vitamine P conférant audit extrait une activité tonicapillaire,
- 5 à 12 % d'extrait liquide d'au moins une plante contenant des flavonoïdes à activité anti -oedémateuse,
- 5 à 12 % d'extrait liquide de prêle,
- 5 à 13 % d'extrait liquide d'au moins une plante contenant des alginates,
- 5 à 12 % d'extrait liquide d'au moins une plante à activité dite tenseur, destinée à affermir le tissu cutané,
- 5 à 12 % d'extrait liquide d'au moins une plante à activité révulsive, et/ou 8 à 20 % d'extrait liquide d'au moins une plante à activité antiinflammatoire.Thus, according to one of its essential characteristics, the invention relates to a mixture of liquid plant extracts containing, expressed in percentages by weight, the following proportions of different liquid plant extracts, each quantity of liquid extracts obtained corresponding to extracting the same amount of fresh plants:
- 8 to 25% of liquid extract from at least one plant containing xanthines giving said extract liporeductive activity,
- 8 to 25% of liquid extract from at least one plant containing a vitamin P analog giving said extract a tonicapillary activity,
- 5 to 12% of liquid extract from at least one plant containing flavonoids with anti-edematous activity,
- 5 to 12% of horsetail liquid extract,
- 5 to 13% of liquid extract from at least one plant containing alginates,
- 5 to 12% of liquid extract from at least one plant with so-called tensor activity, intended to firm the skin tissue,
- 5 to 12% of liquid extract from at least one plant with repulsive activity, and / or 8 to 20% of liquid extract from at least one plant with anti-inflammatory activity.
Au cours de ses recherches, la demanderesse a constaté que l'activité liporéductrice due aux xanthines dépendait considérablement des doses de xanthines comprises dans l'extrait, et qu'en particulier, ces doses ne devaient pas être trop importantes. During its research, the Applicant found that the liporeducing activity due to xanthines depended considerably on the doses of xanthines included in the extract, and that in particular, these doses should not be too great.
C'est pourquoi, parmi les plantes connues pour leur activité liporéductrice due à la présence de xanthines, on préfère selon l'invention celles dont la teneur en xanthines est moyenne. A ce titre, on choisit de préférence selon l'invention comme plante riche en xanthines lui conférant une activité liporéductrice, le thé ou le cola. This is why, among the plants known for their liporeductive activity due to the presence of xanthines, according to the invention, those with an average xanthine content are preferred. As such, preferably chosen according to the invention as a plant rich in xanthines giving it liporeducing activity, tea or cola.
Le thé s'est avéré particulièrement intéressant selon l'invention et ce sont de préférence les feuilles et/ou les bourgeons de thé qui seront utilisés pour préparer les extraits liquides entrant dans les mélanges de l'invention. Tea has proved to be particularly advantageous according to the invention and it is preferably the leaves and / or tea buds which will be used to prepare the liquid extracts used in the mixtures of the invention.
Comme on l'a vu précédemment, les plantes contenant des analogues de vitamine P sont connues pour leur activité tonicapillaire. La naringine possède de façon remarquable cette activité. Cette molécule est avantageusement extraite du pamplemousse. As seen above, plants containing vitamin P analogs are known for their tonicapillary activity. Naringin has this activity remarkably. This molecule is advantageously extracted from grapefruit.
Ainsi, selon l'invention, on choisit avantageusement le pamplemousse comme plante contenant un analogue de vitamine P. Thus, according to the invention, the grapefruit is advantageously chosen as the plant containing a vitamin P analog.
On notera également que le pamplemousse est pour la première fois utilisé dans une composition destinée au traitement local symptomatique des surcharges adipeuses sous cutanées localisées. It will also be noted that grapefruit is used for the first time in a composition intended for the local symptomatic treatment of localized subcutaneous adipose overloads.
Lorsque le pamplemousse est utilisé comme source d'analogue de vitamine P, c'est le fruit en entier qui est utilisé pour l'extraction. When grapefruit is used as a source of vitamin P analog, the whole fruit is used for extraction.
Parmi les différentes plantes connues pour leur application antioedémateuse, à savoir en particulier l'hydrocotyle, la verveine, la piloselle, l'ulmaire, I'orthosiphon, c'est l'ulmaire que l'on choisit de préférence selon l'invention pour la qualité des flavonoïdes contenus dans cette plante. On choisira de préférence pour préparer l'extrait contenant ces flavonoides les feuilles d'ulmaire. Among the various plants known for their anti-edematous application, namely in particular hydrocotyle, verbena, piloselle, ulmaire, orthosiphon, it is the ulmar that is preferably chosen according to the invention for the quality of the flavonoids contained in this plant. We will preferably choose to prepare the extract containing these flavonoids the ulmaire leaves.
Parmi les plantes connues pour leur teneur en alginates, on choisit de préférence le fucus qui associe la présence d'iode organique à l'alginate, améliorant ainsi le facteur de régénération tissulaire. Among the plants known for their alginate content, the fucus is preferably chosen which associates the presence of organic iodine with the alginate, thus improving the tissue regeneration factor.
L'extrait liquide de fucus est de préférence obtenu à partir des thales de cette plante. The liquid extract of fucus is preferably obtained from the thales of this plant.
Parmi les plantes connues pour leur activité tenseur, à savoir l'aigremoine, I'angélique, I'églantier, la marjolaine, la pervenche, le plantain, le lierre grimpant, le ratanhia, la sauge, le géranium, on choisit de préférence le lierre grimpant et l'extraction est, de préférence, réalisée à partir du bois de cette plante, dans des conditions où l'on extrait le principe actif permettant d'assurer l'activité tenseur recherchée, à savoir l'hédérasaponine C. Among the plants known for their tensor activity, namely agremony, angelica, rose hips, marjoram, periwinkle, plantain, climbing ivy, ratanhia, sage, geranium, the climbing ivy and the extraction is preferably carried out from the wood of this plant, under conditions where the active ingredient is extracted, ensuring the desired tightening activity, namely hederasaponin C.
Comme plante à activité révulsive, on choisit de préférence une plante de la famille des renonculacées, de préférence la clématite. On extrait à l'aide d'un solvant ou mélange de solvants le principe actif recherché, à savoir la protoanémonine et/ou l'anémonine. As a plant with revulsive activity, a plant from the renonculaceae family is preferably chosen, preferably clematis. The desired active ingredient, namely protoanemonin and / or anemonon, is extracted using a solvent or mixture of solvents.
Comme plante à activité anti-inflammatoire la réglisse sera choisie pour son caractère à la fois révulsif et anti-inflammatoire. Le principe que l'on extrait à l'aide d'un solvant ou mélange de solvants est l'acide 18ss- glycyrrhétinique. As a plant with anti-inflammatory activity, licorice will be chosen for its both revulsive and anti-inflammatory character. The principle which is extracted using a solvent or mixture of solvents is 18ss-glycyrrhetinic acid.
Selon une variante particulièrement préférée de l'invention, les plantes entrant dans le mélange d'extraits de l'invention sont les suivantes
-Thé (Thea Sinensis L.) choisi pour son activité liporéductrice et sa concentration moyenne en xanthines.According to a particularly preferred variant of the invention, the plants entering into the mixture of extracts of the invention are the following
-Tea (Thea Sinensis L.) chosen for its liporeductive activity and its average concentration of xanthines.
- Fucus (Fucus Vesiculosus L.) choisi pour son activité liporéductrice due à la présence d'iode et pour la présence d'alginate synergique de l'activité de la prêle. - Fucus (Fucus Vesiculosus L.) chosen for its liporeductive activity due to the presence of iodine and for the presence of synergistic alginate of horsetail activity.
- Pamplemousse (Citrus Paradisis M.) choisi pour son activité analogue à celle de la vitamine P grâce à sa très forte concentration en naringine
- Ulmaire (Spiroea Ulmaria L.) choisie pour son activité antioedémateuse complémentaire de l'activité de la naringine. Cette propriété est due aux dérivés flavoniques qu'elle contient, à savoir la spiraeoside et la monotropitoside. - Grapefruit (Citrus Paradisis M.) chosen for its activity similar to that of vitamin P thanks to its very high concentration of naringin
- Ulmaire (Spiroea Ulmaria L.) chosen for its anti-edematous activity complementary to the activity of naringin. This property is due to the flavonic derivatives it contains, namely spiraeoside and monotropitoside.
- Prêle (Equisetum Arvense L.) qui agit sur la synthèse du collagène du fait de la silice qu'elle contient. - Horsetail (Equisetum Arvense L.) which acts on the synthesis of collagen due to the silica it contains.
- Lierre grimpant (Hedera Helix L.) qui a une activité astringente du fait de la présence d'Hédérasaponine C qui permet de compléter l'activité due à la prêle. - Climbing ivy (Hedera Helix L.) which has an astringent activity due to the presence of Hedasaponin C which makes it possible to complete the activity due to horsetail.
- Clématite (Clematis Vitalba L.) qui agit comme révulsif du fait de la présence de la protoanémonine. - Clematis (Clematis Vitalba L.) which acts as a repellent due to the presence of protoanemonin.
- Réglisse (Glycyrrhiza glabra L.) dont l'acide 18ss-glycyrrhétinique possède une forte activité anti-inflammatoire et par la même la propriété d'augmenter la pénétration percutanée des substances appliquées sur la peau. - Licorice (Glycyrrhiza glabra L.) whose 18ss-glycyrrhetinic acid has a strong anti-inflammatory activity and at the same time the property of increasing the percutaneous penetration of substances applied to the skin.
Les mélanges d'extraits de plantes ci-dessus contiennent, de préférence, les proportions suivantes des différents extraits liquides de plantes -thé: 8à25 %
- pamplemousse : 8 à 25 %
- fucus : 5 à 12 %
- ulmaire : 5 à 12 %
- prêle : 5 à 12 %
- lierre grimpant : 5 à 12 %
- clématite : 5 à 12 % et/ou réglisse : 8 à 20 %.The mixtures of plant extracts above contain, preferably, the following proportions of the various liquid plant extracts-tea: 8 to 25%
- grapefruit: 8 to 25%
- wrack: 5 to 12%
- ulcer: 5 to 12%
- horsetail: 5 to 12%
- climbing ivy: 5 to 12%
- clematis: 5 to 12% and / or licorice: 8 to 20%.
Les différents extraits liquides de plantes sont obtenus de façon bien connue de l'homme du métier par traitement des parties concemées des plantes par un solvant ou un mélange de solvant choisi pour son aptitude à extraire la fraction active concernée. The various liquid plant extracts are obtained in a manner well known to those skilled in the art by treatment of the concerned parts of the plants with a solvent or a mixture of solvents chosen for its ability to extract the active fraction concerned.
Le choix du solvant et les conditions de l'extraction, en particulier la température et la durée de l'extraction, dépendent donc étroitement de la nature de la plante retenue. Toutefois, pour chaque plante utile selon l'invention, on choisira, de préférence, le solvant parmi l'eau, les alcools non toxiques et les mélanges de ces alcools avec de l'eau. The choice of solvent and the conditions of the extraction, in particular the temperature and the duration of the extraction, therefore closely depend on the nature of the plant selected. However, for each plant useful according to the invention, the solvent will preferably be chosen from water, non-toxic alcohols and mixtures of these alcohols with water.
Ces alcools sont avantageusement choisis parmi l'éthanol, le propylèneglycol, le 1,3-butylèneglycol, et le 3-méthoxy-3-méthyl-1-butanol. These alcohols are advantageously chosen from ethanol, propylene glycol, 1,3-butylene glycol, and 3-methoxy-3-methyl-1-butanol.
Selon le principe actif et sa solubilité, les proportions des phases extractives aqueuses et alcooliques seront choisies en fonction du principe actif et de sa solubilité. Depending on the active principle and its solubility, the proportions of the aqueous and alcoholic extractive phases will be chosen according to the active principle and its solubility.
Chacun des extraits liquides partiels constituant le mélange d'extraits liquides selon l'invention comprendra avantageusement de 20 à 65 % de phase aqueuse extractive. Each of the partial liquid extracts constituting the mixture of liquid extracts according to the invention will advantageously comprise from 20 to 65% of extractive aqueous phase.
En effet, comme il est bien connu lorsqu'il s'agit d'extraits de plantes destinés à une phytothérapie, on cherche avant tout à extraire des plantes sélectionnées la majeure partie de la fraction active recherchée. C'est pourquoi, on cherche avantageusement à prendre les organes privilégiés de plantes fraîches ou séchées du fait de leur richesse en principe actif sélectionné. Ainsi dans le cas des plantes sélectionnées, on choisira de préférence
- pour le lierre grimpant, son bois,
- pour l'ulmaire, les fleurs,
- pour la clématite, les feuilles et/ou les fleurs,
- pour le fucus, les thales,
- pour le pamplemousse, le fruit entier,
- pour le thé, les feuilles et/ou les bourgeons,
- pour la prêle, les feuilles,
- pour le réglisse, le bois.Indeed, as is well known when it comes to plant extracts intended for phytotherapy, the main aim is to extract from selected plants the major part of the active fraction sought. This is why, it is advantageously sought to take the preferred organs of fresh or dried plants because of their richness in active ingredient selected. So in the case of selected plants, we will preferably choose
- for climbing ivy, its wood,
- for the ulmar, the flowers,
- for clematis, leaves and / or flowers,
- for the wrack, the thales,
- for grapefruit, whole fruit,
- for tea, leaves and / or buds,
- for horsetail, leaves,
- for liquorice, wood.
Pour la préparation de chacun des extraits que l'on mélange ensuite, on broie les parties de plantes sélectionnées de façon à permettre une extraction optimale par le solvant choisi et on réalise l'extraction à une température comprise généralement entre 30 et 50iC en fonction de la nature de la plante et du milieu solvant retenu. La durée du traitement par le solvant est calculée de façon à assurer un contact suffisant pour une extraction complète de la fraction active visée. For the preparation of each of the extracts which are then mixed, the parts of the selected plants are ground so as to allow optimal extraction with the chosen solvent and the extraction is carried out at a temperature generally between 30 and 50 ° C. depending on the nature of the plant and of the solvent medium retained. The duration of the treatment with the solvent is calculated so as to ensure sufficient contact for complete extraction of the targeted active fraction.
Comme il a été précisé, en fonction du principe actif et de sa solubilité, il sera donné plus ou moins d'importance à une phase extractive par rapport à l'autre. Ainsi, par exemple, dans le cas de la préparation de l'extrait de pamplemousse, les deux phases extractives seront avantageusement dans la proportion de 40 % de phase alcoolique pour 60 % de phase aqueuse. As has been specified, depending on the active principle and its solubility, more or less importance will be given to one extractive phase with respect to the other. Thus, for example, in the case of the preparation of the grapefruit extract, the two extractive phases will advantageously be in the proportion of 40% of alcoholic phase for 60% of aqueous phase.
Les extraits liquides préparés sont ensuite mélangés pour former le mélange selon l'invention. The liquid extracts prepared are then mixed to form the mixture according to the invention.
On ajoute ensuite avantageusement un conservateur au mélange d'extraits liquides. A preservative is then advantageously added to the mixture of liquid extracts.
Ce conservateur peut être tout conservateur connu pour ce type d'application, par exemple un mélange de phénoxyéthanol, méthylparaben, butylparaben, éthylparaben et propylparaben, bien connu sous le nom commercial
Phénonip.This preservative can be any preservative known for this type of application, for example a mixture of phenoxyethanol, methylparaben, butylparaben, ethylparaben and propylparaben, well known under the trade name.
Phenonip.
Ce conservateur est ajouté de préférence à des teneurs comprises entre 0,2 et 0,5 % en poids par rapport au mélange d'extraits liquides. This preservative is preferably added in contents of between 0.2 and 0.5% by weight relative to the mixture of liquid extracts.
Selon un autre de ses aspects essentiels, I'invention concerne également l'utilisation des mélanges d'extraits liquides décrits précédemment pour préparer des compositions à activité cosmétique ou pharmaceutique, notamment dermatologique, destinéees à une action topique. Ces compositions contiennent de préférence de 5 à 70 % en poids d'un mélange tel que défini précédemment et un véhicule cosmétiquement ou pharmaceutiquement acceptable. According to another of its essential aspects, the invention also relates to the use of the mixtures of liquid extracts described above for preparing compositions with cosmetic or pharmaceutical activity, in particular dermatological activity, intended for topical action. These compositions preferably contain from 5 to 70% by weight of a mixture as defined above and a cosmetically or pharmaceutically acceptable vehicle.
A titre d'exemple de ces compositions, on citera des laits, des crèmes, des gels. By way of example of these compositions, mention may be made of milks, creams, gels.
L'invention concerne tout particulièrement les compositions à activité cosmétique contenant les mélanges d'extraits définis précédemment ainsi qu'un procédé de traitement cosmétique, notamment destiné au traitement local symptomatique des surcharges adipeuses sous-cutanées localisées, qui consiste à appliquer sur les parties du corps concemées une quantité efficace d'un mélange tel que défini précédemment ou d'une composition cosmétique telle que définie précédemment. The invention relates very particularly to compositions with cosmetic activity containing the mixtures of extracts defined above as well as a cosmetic treatment method, in particular intended for the local symptomatic treatment of localized subcutaneous adipose overloads, which consists in applying to the parts of the body concerned an effective amount of a mixture as defined above or of a cosmetic composition as defined above.
Les compositions définies précédemment permettent notamment le traitement des surcharges adipeuses sous-cutanées ou lipodystrophies localisées de type gynoïde, localisées notamment dans les régions rétrodeltoïdienne, mammaire, sous-ombilicale, fessière, rétrosacrée, aux niveaux des hanches ou des cuisses. The compositions defined above allow in particular the treatment of subcutaneous adipose overloads or localized lipodystrophies of gynoid type, localized in particular in the retrodeltoid, mammary, sub-umbilical, gluteal, gluteal regions, at the hips or thighs.
L'efficacité des extraits et compositions de l'invention a été mise en évidence au moyen d'un test à la fois simple et significatif décrit ci-dessous dans le cas des surcharges adipeuses sous-cutanées localisées au niveau des cuisses (face antérieure et face interne, à la racine du genou). The effectiveness of the extracts and compositions of the invention has been demonstrated by means of a test which is both simple and significant, described below in the case of subcutaneous adipose overloads located at the level of the thighs (anterior and inner face, at the root of the knee).
On détermine sur la face externe, 20 cm au-dessus de l'articulation un point dont la matérialité est signifiée par une marque d'encre indélébile sur une période d'environ 3 mois. Au niveau de ce point, on mesure régulièrement au cours du traitement local par le produit la circonférence de la cuisse et on note les variations observées. A point is determined on the external face, 20 cm above the joint, the materiality of which is signified by an indelible ink mark over a period of approximately 3 months. At this point, the circumference of the thigh is regularly measured during local treatment with the product and the variations observed are noted.
Claims (13)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9514702A FR2742055B1 (en) | 1995-12-12 | 1995-12-12 | MIXTURE OF PLANT EXTRACTS AND THEIR USES, IN PARTICULAR FOR THE SYMPTOMATIC LOCAL TREATMENT OF LOCALIZED SUBCUTANEOUS ADIPOSE OVERLOADS |
JP8351815A JPH09291038A (en) | 1995-12-12 | 1996-12-12 | Mixture of plant extract including treatment of local part of symptom of local excessive skinfold thickness and its use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9514702A FR2742055B1 (en) | 1995-12-12 | 1995-12-12 | MIXTURE OF PLANT EXTRACTS AND THEIR USES, IN PARTICULAR FOR THE SYMPTOMATIC LOCAL TREATMENT OF LOCALIZED SUBCUTANEOUS ADIPOSE OVERLOADS |
Publications (2)
Publication Number | Publication Date |
---|---|
FR2742055A1 true FR2742055A1 (en) | 1997-06-13 |
FR2742055B1 FR2742055B1 (en) | 1998-02-27 |
Family
ID=9485404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR9514702A Expired - Lifetime FR2742055B1 (en) | 1995-12-12 | 1995-12-12 | MIXTURE OF PLANT EXTRACTS AND THEIR USES, IN PARTICULAR FOR THE SYMPTOMATIC LOCAL TREATMENT OF LOCALIZED SUBCUTANEOUS ADIPOSE OVERLOADS |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPH09291038A (en) |
FR (1) | FR2742055B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2849775A1 (en) * | 2003-01-09 | 2004-07-16 | Gattefosse Ets Sa | Use of cirsimarin or cirsimaritin for activating lipolysis, especially useful as active agents in cosmetic compositions for topical treatment of cellulite comprise |
FR2872041A1 (en) * | 2004-06-25 | 2005-12-30 | Maurice Messegue Soc Par Actio | Agent for promoting cutaneous penetration of topically applied cosmetic or pharmaceutical active agents, comprising extract of cells of Ranunculaceae plant, especially lesser celandine |
FR2886546A1 (en) * | 2005-06-03 | 2006-12-08 | Henri Lazarini | Cosmetic or pharmaceutical composition, useful as a slimming agent to treat obesity, to prevent or treat the cellulitis and/or orange skin and/or to refine the figure or the face, comprises vegetable e.g. Hedera helix extract |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4034011B2 (en) * | 1999-08-10 | 2008-01-16 | 株式会社ナリス化粧品 | Cosmetics |
US20030054015A1 (en) * | 2000-12-25 | 2003-03-20 | Shinichiro Haze | Sympathetic-activating perfume composition |
JP4611565B2 (en) * | 2001-03-30 | 2011-01-12 | 株式会社ナリス化粧品 | Fat synthesis accelerator and cosmetics |
KR102221265B1 (en) * | 2019-10-10 | 2021-03-04 | 한국과학기술연구원 | Food compositions and pharmaceutical compositions containing Filipendula glaberrima extract for lowering blood cholesterol levels and for improving atherosclerosis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4569839A (en) * | 1981-02-27 | 1986-02-11 | L'oreal | Cosmetic compositions for the treatment of the hair and skin contain in the form of a powder particles resulting from the pulverization of at least one plant substance and a cohesion agent |
EP0665001A1 (en) * | 1993-12-30 | 1995-08-02 | L'oreal | Topical slimming composition containing two types of liposomes and its use |
-
1995
- 1995-12-12 FR FR9514702A patent/FR2742055B1/en not_active Expired - Lifetime
-
1996
- 1996-12-12 JP JP8351815A patent/JPH09291038A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4569839A (en) * | 1981-02-27 | 1986-02-11 | L'oreal | Cosmetic compositions for the treatment of the hair and skin contain in the form of a powder particles resulting from the pulverization of at least one plant substance and a cohesion agent |
EP0665001A1 (en) * | 1993-12-30 | 1995-08-02 | L'oreal | Topical slimming composition containing two types of liposomes and its use |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2849775A1 (en) * | 2003-01-09 | 2004-07-16 | Gattefosse Ets Sa | Use of cirsimarin or cirsimaritin for activating lipolysis, especially useful as active agents in cosmetic compositions for topical treatment of cellulite comprise |
WO2004069217A1 (en) * | 2003-01-09 | 2004-08-19 | Gattefosse Sas | Cosmetic composition based on cirsimarin |
FR2872041A1 (en) * | 2004-06-25 | 2005-12-30 | Maurice Messegue Soc Par Actio | Agent for promoting cutaneous penetration of topically applied cosmetic or pharmaceutical active agents, comprising extract of cells of Ranunculaceae plant, especially lesser celandine |
FR2886546A1 (en) * | 2005-06-03 | 2006-12-08 | Henri Lazarini | Cosmetic or pharmaceutical composition, useful as a slimming agent to treat obesity, to prevent or treat the cellulitis and/or orange skin and/or to refine the figure or the face, comprises vegetable e.g. Hedera helix extract |
Also Published As
Publication number | Publication date |
---|---|
FR2742055B1 (en) | 1998-02-27 |
JPH09291038A (en) | 1997-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CH648492A5 (en) | STABLE EMULSIONS OBTAINED FROM A NATURAL EMULSIFYING AGENT STABILIZED BY ALOE SUC. | |
EP1001740B1 (en) | USE OF THE Rb 1 GINSENOSIDE FOR STIMULATING ELASTIN SYNTHESIS | |
FR2676649A1 (en) | COSMETIC OR PHARMACEUTICAL COMPOSITION, ESPECIALLY DERMATOLOGICAL, FOR PROMOTING PIGMENTATION OF THE SKIN OR HAIR, CONTAINING A CYPERUS EXTRACT AND PROCESS FOR PRODUCING THE SAME. | |
FR2671487A1 (en) | USE OF A GROWTH FACTOR IN A SLIMMING COMPOSITION. | |
EP0595988B1 (en) | Cosmetic compositions comprising an extract of eclipta alba | |
CA2566905A1 (en) | Association of vegetal extracts based on gooseberries, black orchids and black tulips and topical composition comprising the association of said vegetal extracts | |
EP0673238B1 (en) | Use of a simarouba extract to reduce patchy skin pigmentation | |
FR2934160A1 (en) | PROCESS FOR THE PREPARATION OF LIPOPHILIC VINE EXTRACT | |
EP1768684B1 (en) | Composition comprising a blue lotus extract for the treatment of facial uncontrolled muscular contractions | |
FR2742055A1 (en) | Liquid plant extract mixture | |
EP1811953B1 (en) | Novel use of chaulmoogra oil and guggulipids in therapeutics and cosmetics | |
EP2291173B1 (en) | Combination of passion flower and alkanet extracts for use in cosmetics | |
FR3013985A1 (en) | MOISTURIZING COMPOSITIONS COMPRISING AT LEAST ONE CAESALPINIA SPINOSA EXTRACT WITH AT LEAST VASELIN AND GLYCERIN | |
FR2665637A1 (en) | Cosmetic or pharmaceutical composition containing an extract of Coleus esquirolii, Coleus scutellarioides, Coleus xanthanthus or a mixture thereof | |
WO2000030604A1 (en) | Composition for preventing and treating cellulitis | |
FR3063905A1 (en) | USE OF COPAIFERA IN COSMETICS AND DERMATOLOGY | |
FR3055214A1 (en) | LIGHTENING COSMETIC COMPOSITION | |
FR2759910A1 (en) | Cosmetic and dermo-pharmaceutical use of extracts of Kigelia africana | |
WO2009101301A2 (en) | Use of a poppy petal extract for skin nutrition | |
FR2700268A1 (en) | Cosmetic or pharmaceutical composition, especially dermatological, containing an extract of Vismia. | |
WO1994015626A9 (en) | Cosmetic or pharmaceutical and particularly dermatological composition containing a vismia extract | |
FR2974298A1 (en) | VEGETABLE EXTRACT COMPLEX FOR SKIN PROTECTION | |
FR2876909A1 (en) | Cosmetic and/or pharmaceutical composition, to prevent or treat adipose overloads and cellulitis, comprises a combination of one or more xanthinic bases and chaulmoogra oil and/or its components | |
FR2871382A1 (en) | Topical cosmetic/dermatological composition, useful to fight against the signs of aging, comprises a complex extract of blue lotus and poppy | |
EP1703889B1 (en) | Cosmetic or pharmaceutical use of a cork hydrolysis extract |